Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 347-360 , June 2009

Diabetic cardiomyopathy – a distinct disease?

  • Kaivan Khavandi, MRes (Hon. Research Fellow, Cardiovascular Medicine)

      Affiliations

    • Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd floor), 46 Grafton Street, University of Manchester, UK
    • ,
  • Ali Khavandi, MBChB, MRCP (Specialist Registrar, Cardiology)

      Affiliations

    • Department of Cardiology, Bristol Royal Infirmary, Marlborough Street, Bristol, UK
    • ,
  • Omar Asghar, MBChB, MRCP (Specialist Registrar, Cardiovascular Medicine)

      Affiliations

    • Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd floor), 46 Grafton Street, University of Manchester, UK
    • ,
  • Adam Greenstein, MBChB, BSc (Hons), MRCP (Clinical Lecturer, Cardiovascular Medicine)

      Affiliations

    • Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd floor), 46 Grafton Street, University of Manchester, UK
    • ,
  • Sarah Withers, BSc (Hons), PhD (Research Associate)

      Affiliations

    • Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd floor), 46 Grafton Street, University of Manchester, UK
    • ,
  • Anthony M. Heagerty, MBBS, MD, FRCP, FAHA, FMedSci (Professor of Medicine and Hon. Consultant Physician)

      Affiliations

    • Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd floor), 46 Grafton Street, University of Manchester, UK
    • ,
  • Rayaz A. Malik, MBChB, BSc (Hons), MSc, PhD, FRCP (Professor of Medicine and Hon. Consultant Physician)

      Affiliations

    • Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd floor), 46 Grafton Street, University of Manchester, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 161 275 1196; Fax: +44 161 275 1183.

References 

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 Sep;21(9):1414–1431
  2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 1998 Jul 23;339(4):229–234
  3. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology. 1972 Nov 8;30(6):595–602
  4. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. American Journal of Cardiology. 1974 Jul;34(1):29–34
  5. Hayat SA, Patel B, Khattar RS, et al. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clinical Science. 2004 Dec;107(6):539–557
  6. De Groote P, Lamblin N, Mouquet F, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. European Heart Journal. 2004 Apr;25(8):656–662
  7. Berry C, Brett M, Stevenson K, et al. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart. 2008 Mar;94(3):296–304
  8. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. American Journal of Cardiology. 1996 May 1;77(11):1017–1020
  9. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. [see comment] New England Journal of Medicine. 1990 May 31;322(22):1561–1566
  10. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal. 2007 Oct;28(20):2539–2550
  11. Petrie MC, Caruana L, Berry C, et al. ‘Diastolic heart failure’ or heart failure caused by subtle left ventricular systolic dysfunction?. Heart. 2002 Jan;87(1):29–31
  12. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology. 2003 Sep 3;42(5):914–922
  13. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. New England Journal of Medicine. 2006 Jul 20;355(3):260–269
  14. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006 Jul 20;355(3):251–259
  15. Lam CSP, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. [erratum appears in Circulation. 2007 May 22;115(20):e535] Circulation. 2007 Apr 17;115(15):1982–1990
  16. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction. A prospective 5-year study. Heart. 2008;January 20, 2008:hrt.2007.128769
  17. Shishehbor MH, Hoogwerf BJ, Schoenhagen P, et al. Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. American Journal of Cardiology. 2003 Jun 15;91(12):1514–1517
  18. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. Journal of the American College of Cardiology. 2006 Oct 17;48(8):1548–1551
  19. Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. [see comment] Diabetes Care. 2001 Jan;24(1):5–10
  20. Badano LP, Albanese MC, De Biaggio P, et al. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. Journal of the American Society of Echocardiography. 2004 Mar;17(3):253–261
  21. Tsang TSM, Barnes ME, Gersh BJ, et al. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. American Journal of Cardiology. 2002 Dec 15;90(12):1284–1289
  22. Di Bonito P, Moio N, Cavuto L, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabetic Medicine. 2005 Dec;22(12):1720–1725
  23. Rademakers FE. Magnetic resonance imaging in cardiology. Lancet. 2003 Feb 1;361(9355):359–360
  24. Hammer S, van der Meer RW, Lamb HJ, et al. Short-term Flexibility of Myocardial Triglycerides and Diastolic Function in Patients with Type 2 Diabetes Mellitus. American Journal of Physiology. Endocrinology and Metabolism. 2008;July 15, 2008:90413.2008
  25. Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. New England Journal of Medicine. 1980 Feb 14;302(7):384–388
  26. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001 Jun 5;103(22):2668–2673
  27. Van den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. European Journal of Heart Failure. 2006 Dec;8(8):777–783
  28. Greer JJM, Ware DP, Lefer DJ. Myocardial infarction and heart failure in the db/db diabetic mouse. American Journal of Physiology - Heart & Circulatory Physiology. 2006 Jan;290(1):H146–H153
  29. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007 Jun 26;115(25):3213–3223
  30. Konduracka E, Gackowski A, Rostoff P, et al. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. [see comment] European Heart Journal. 2007 Oct;28(20):2465–2471
  31. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007 Aug;93(8):903–907
  32. Wold LE, Ceylan-Isik AF, Fang CX, et al. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radical Biology & Medicine. 2006 Apr 15;40(8):1419–1429
  33. Liang Q, Carlson EC, Donthi RV, et al. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes. 2002 Jan;51(1):174–181
  34. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. Journal of the American College of Cardiology. 2006 Oct 17;48(8):1688–1697
  35. Ye G, Metreveli NS, Donthi RV, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes. 2004 May;53(5):1336–1343
  36. Gao WD, Liu Y, Marban E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation. 1996 Nov 15;94(10):2597–2604
  37. Li J-M, Gall NP, Grieve DJ, et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002 Oct;40(4):477–484
  38. Ritchie RH, Quinn JM, Cao AH, et al. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. Journal of Molecular & Cellular Cardiology. 2007 Jun;42(6):1119–1128
  39. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. Journal of Clinical Investigation. 1991 May;87(5):1643–1648
  40. Duncan ER, Walker SJ, Ezzat VA, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. American Journal of Physiology - Endocrinology & Metabolism. 2007 Nov;293(5):E1311–E1319
  41. Hornig B, Arakawa N, Kohler C, et al. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998 Feb 3;97(4):363–368
  42. MacCarthy PA, Grieve DJ, Li JM, et al. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation. 2001 Dec 11;104(24):2967–2974
  43. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. [see comment] New England Journal of Medicine. 2000 Jan 20;342(3):154–160
  44. Yang Z, Zingarelli B, Szabo C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock. 2000 Jan;13(1):60–66
  45. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. [see comment] Journal of Clinical Investigation. 2003 Oct;112(7):1049–1057
  46. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News & Perspectives. 2002;15:197–205
  47. Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB Journal. 2003 Aug;17(11):1514–1516
  48. Chiu J, Farhangkhoee H, Xu BY, et al. PARP mediates structural alterations in diabetic cardiomyopathy. Journal of Molecular and Cellular Cardiology. 2008 Sep;45(3):385–393
  49. Soriano FG, Pacher P, Mabley J, et al. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circulation Research. 2001 Oct 12;89(8):684–691
  50. Bowling N, Walsh RA, Song G, et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation. 1999 Jan 26;99(3):384–391
  51. Way KJ, Isshiki K, Suzuma K, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes. 2002 Sep;51(9):2709–2718
  52. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998 Jun;47(6):859–866
  53. Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. [see comment] Nature Medicine. 2004 Mar;10(3):248–254
  54. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America. 1997 Aug 19;94(17):9320–9325
  55. Topham MK, Prescott SM. Diacylglycerol kinases: regulation and signaling roles. Thrombosis & Haemostasis. 2002 Dec;88(6):912–918
  56. Harada M, Takeishi Y, Arimoto T, et al. Diacylglycerol kinase zeta attenuates pressure overload-induced cardiac hypertrophy. Circulation Journal. 2007 Feb;71(2):276–282
  57. Bilim O, Takeishi Y, Kitahara T, et al. Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. Cardiovascular Diabetology. 2008;7:2
  58. Xia Z, Kuo K-H, Nagareddy PR, et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovascular Research. 2007 Mar 1;73(4):770–782
  59. Hambleton M, Hahn H, Pleger ST, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006 Aug 8;114(6):574–582
  60. Arikawa E, Ma RCW, Isshiki K, et al. Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes. 2007 May;56(5):1410–1420
  61. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002 Jan 10;415(6868):198–205
  62. Trost SU, Belke DD, Bluhm WF, et al. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002 Apr;51(4):1166–1171
  63. Hattori Y, Matsuda N, Kimura J, et al. Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. Journal of Physiology. 2000 Aug 15;527(Pt 1):85–94
  64. Pereira L, Matthes J, Schuster I, et al. Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes. 2006 Mar;55(3):608–615
  65. Golfman L, Dixon IM, Takeda N, et al. Cardiac sarcolemmal Na(+)-Ca2+ exchange and Na(+)-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats. Molecular & Cellular Biochemistry. 1998 Nov;188(1-2):91–101
  66. Vetter R, Rehfeld U, Reissfelder C, et al. Transgenic overexpression of the sarcoplasmic reticulum Ca2 + ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB Journal. 2002 Oct;16(12):1657–1659
  67. Yaras N, Bilginoglu A, Vassort G, et al. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. American Journal of Physiology - Heart & Circulatory Physiology. 2007 Feb;292(2):H912–H920
  68. Jweied EE, McKinney RD, Walker LA, et al. Depressed cardiac myofilament function in human diabetes mellitus. American Journal of Physiology - Heart & Circulatory Physiology. 2005 Dec;289(6):H2478–H2483
  69. Qin D, Huang B, Deng L, et al. Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy. Biochemical & Biophysical Research Communications. 2001 May 11;283(3):549–553
  70. Cooper GJS, Phillips ARJ, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes. 2004 Sep;53(9):2501–2508
  71. Dostal DE, Rothblum KN, Chernin MI, et al. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. American Journal of Physiology. 1992 Oct;263(4 Pt 1):C838–C850
  72. Privratsky JR, Wold LE, Sowers JR, et al. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension. 2003 Aug;42(2):206–212
  73. Raimondi L, De Paoli P, Mannucci E, et al. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes. 2004 Jul;53(7):1927–1933
  74. Fiordaliso F, Cuccovillo I, Bianchi R, et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sciences. 2006 Jun 6;79(2):121–129
  75. Liu X, Suzuki H, Sethi R, et al. Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Annals of the New York Academy of Sciences. 2006 Nov;1084:141–154
  76. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. [see comment][erratum appears in Lancet 2000 Sep 2;356(9232):860] Lancet. 2000 Jan 22;355(9200):253–259
  77. Kajstura J, Fiordaliso F, Andreoli AM, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes. 2001 Jun;50(6):1414–1424
  78. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. [erratum appears in Circulation 2001 Jan 23;103(3):476] Circulation. 2000 Nov 28;102(22):2700–2706
  79. McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998 Dec 15;98(24):2765–2773
  80. Neumann S, Huse K, Semrau R, et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension. 2002 Mar 1;39(3):756–760
  81. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circulation Research. 1995 Sep;77(3):638–643
  82. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. Journal of Biological Chemistry. 2000 Sep 1;275(35):26765–26771
  83. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999 May 4;99(17):2239–2242
  84. Shinohara K, Shinohara T, Mochizuki N, et al. Expression of vascular endothelial growth factor in human myocardial infarction. Heart & Vessels. 1996;11(3):113–122
  85. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation. 2002 Jan 22;105(3):373–379
  86. Emoto M, Anno T, Sato Y, et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001 May;50(5):1166–1170
  87. Ebrahimian TG, Heymes C, You D, et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. American Journal of Pathology. 2006 Aug;169(2):719–728
  88. Jesmin S, Zaedi S, Shimojo N, et al. Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. American Journal of Physiology - Endocrinology & Metabolism. 2007 Apr;292(4):E1030–E1040
  89. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. [see comment][erratum appears in 2000 May 4;342(18):1376] New England Journal of Medicine. 2000 Jan 20;342(3):145–153
  90. Cohn JN, Tognoni G, Valsartan Heart Failure Trial I . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. [see comment] [summary for patients in J Card Fail. 2002 Apr;8(2):56–8; PMID: 12016625] New England Journal of Medicine. 2001 Dec 6;345(23):1667–1675
  91. Haas SJ, Vos T, Gilbert RE, et al. Are [beta]-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. American Heart Journal. 2003;146(5):848–853
  92. Werner CM, Bohm M. Review: the therapeutic role of RAS blockade in chronic heart failure. Therapeutic Advances in Cardiovascular Disease. 2008;2(3):167–177
  93. Warner JG, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. Journal of the American College of Cardiology. 1999 May;33(6):1567–1572
  94. Pieske BA, Wachter RB. Impact of diabetes and hypertension on the heart. Current Opinion in Cardiology. July 2008;23(4):340–349
  95. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. [see comment] [erratum appears in Lancet 1999 Aug 14;354(9178):602] Lancet. 1998 Sep 12;352(9131):837–853
  96. Group UKPDS . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713
  97. Action to Control Cardiovascular Risk in Diabetes Study G , Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. [see comment] New England Journal of Medicine. 2008 Jun 12;358(24):2545–2559
  98. Group AC , Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. [see comment] New England Journal of Medicine. 2008 Jun 12;358(24):2560–2572
  99. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). [see comment] European Heart Journal. 2007 Jan;28(1):88–136
  100. Sasso FC, Carbonara O, Cozzolino D, et al. Effects of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients: a radionuclide ventriculographic study. Journal of the American College of Cardiology. 2000 Jul;36(1):219–226
  101. Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. American Journal of Hypertension. 2005 Jul;18(7):949–957
  102. Cobitz A, Zambanini A, Sowell M, et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiology and Drug Safety. 2008;17(8):769–781
  103. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [see comment] [erratum appears in N Engl J Med. 2007 Jul 5;357(1):100] New England Journal of Medicine. 2007 Jun 14;356(24):2457–2471
  104. Investigators DT, Dagenais GR, Gerstein HC, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008 May;31(5):1007–1014
  105. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. Journal of the American College of Cardiology. 2008 Jan 29;51(4):415–426
  106. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. [see comment] New England Journal of Medicine. 2007 Nov 29;357(22):2248–2261

PII: S1521-690X(08)00146-2

doi: 10.1016/j.beem.2008.10.016

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 347-360 , June 2009

Article Tools

* Image Usage & Resolution